Evaluation of Retinal and Vascular Features in Macular Degeneration After Intravitreal Injections of Bevacizumab
Study of Retinal and Vascular Features by Optical Coherence Tomography and Optical Coherence Tomography Angiography After Intravitreal Injections of Bevacizumab in Exudative Age-related Macular Degeneration
研究概览
详细说明
Bevacizumab is a vascular endothelial growth factor antagonist represent an efficacy treatment for exudative age-related macular degeneration acting on vascular hyperpermeability.
The optical coherence tomography and optical coherence tomography angiography represent novel and non-invasive diagnostic techniques that allow a detailed and quantitative analysis of retinal and vascular features.
The study evaluates the changes in optical coherence tomography and optical coherence tomography angiography parameters at baseline and after three monthly injections of Bevacizumab in exudative AMD.
研究类型
注册 (实际的)
联系人和位置
学习地点
-
-
-
Naples、意大利、80100
- University of Naples "Federico II"
-
-
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
描述
Inclusion Criteria:
- age older than 50 years, diagnosis of exudative age-related macular degeneration, treatment-naïve with Bevacizumab for exudative age-related macular degeneration.
Exclusion Criteria:
- age younger than 50 years, diagnosis of exudative macular degeneration due to other causes, previous treatments before Bevacizumab for exudative age-related macular degeneration.
学习计划
研究是如何设计的？
设计细节
- 观测模型：队列
- 时间观点：预期
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
Patients receiving Bevacizumab
Bevacizumab, intravitreal injection, three monthly, dosage: 1.25 mg/0.05
mL.
|
Three monthly intravitreal injections of bevacizumab (1.25 mg/0.05
mL)
其他名称：
|
研究衡量的是什么？
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Study of retinal structural features in exudative age-related macular degeneration after intravitreal injections of Bevacizumab
大体时间：three months
|
The effectiveness of Bevacizumab injections for treating exudative age-related macular degeneration using optical coherence tomography.
The parameters analyzed by optical coherence tomography: Central Macular Thickness and Subfoveal Choroidal thickness (microns).
|
three months
|
|
Study of retinal vascular features in exudative age-related macular degeneration after intravitreal injections of Bevacizumab
大体时间：three months
|
The effectiveness of Bevacizumab injections for treating exudative age-related macular degeneration using optical coherence tomography angiography.
The parameters analyzed by optical coherence tomography angiography were: retinal and choriocapillaris vessel density (%).
|
three months
|
合作者和调查者
调查人员
- 首席研究员：Gilda Cennamo, MD、Federico II University
研究记录日期
研究主要日期
学习开始 (实际的)
初级完成 (实际的)
研究完成 (实际的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
此信息直接从 clinicaltrials.gov 网站检索，没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求，请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改，我们的网站上也会自动更新.